Table 2.
Basic characteristics of the studies included in the meta-analysis (n = 51).
| Study | Cancer type | Median PFS (ATB vs non-ATB) |
Median OS (ATB vs non-ATB) |
NOS score |
| A. Iglesias‐Santamariía (12) | locally advanced/metastatic cancer | 4.3 months vs. 5.8 months | 11.7 months vs. 14.5 months, | 7 |
| Akhil Kapoor (13) | Lung cancer, head and neck cancer, others |
3.6 months vs 1.7 months | 3.9 months vs 9.2 months | 6 |
| Aly-Khan A. Lalani (14) | mRCC | 7.2 months vs NK | 12.0 months vs NK | 7 |
| Amit A Kulkarni (15) | NSCLC, RCC, AML |
1.5 months vs 4.0 months | 3.0 months vs 12.0 months | 7 |
| Andrew F. Nyein (16) | NSCLC | NK | NK | 6 |
| Angelo Castello (17) | NSCLC | 4.1 months vs 12.4 months | 11.3 months vs 15.3 months | 8 |
| Anne Schett (18) | NSCLC | 1.9 months vs 3.8 months | 7.9 months vs 23.6 months | 8 |
| Arielle Elkrief (19) | melanoma | 2.4 months vs 7.3 months | 7.5 months vs 18.3 months | 8 |
| Bertrand Routy (20) | NSCLC, RCC, urothelial carcinoma |
3.5 months vs 4.1 months | 11.5 months vs 20.6 months | 8 |
| C Hogue (21) | NSCLC | NK | NK | 6 |
| Coureche Kaderbhai (22) | NSCLC | NK | NK | 7 |
| David J. Pinato (23) | Primary lung, Clear cell renal cell carcinoma, Primary head and neck squamous cell carcinoma Malignant melanoma, Transitional cell carcinoma |
NK | 14.6 months vs NK | 7 |
| Deniz Can Guve (24) | RCC | 23.75 ± 4.41 months | 8.44 ± 1.61 months | 8 |
| F. Barroín (25) | NSCLC | 1.9 months vs 2.7 months | 2.04 months vs 12.42 months | 9 |
| Florian Huemer (26) | NSCLC | 3.8 months vs 4.0 months | 14.6 months vs 11.2 months | 8 |
| Florian Huemer (27) | NSCLC | 2.9 months vs 3.1 months | 7.5 months vs 15.1 months | 9 |
| Hyunho Kim (28) | Non-small-cell lung carcinoma | 2 months vs 4 months | 5 months vs 17 months | 8 |
| Jahan J. Mohiuddin (29) | melanoma | NK | 27.4 months vs 43.7 months | 7 |
| Jhe-cyuan Guo (30) | ESCC | 1.3 months vs 2.8 months | 3.0 months vs 10.4 months | 8 |
| Jibran Ahmed (31) | Lung cancer, Renal cancer Hepatocellular cancer Head and neck cancer Urothelial cancer Malignant melanoma |
NK | 24 weeks vs 89 weels | 7 |
| Julia Ouaknine Krief (32) | non-small cell lung cancer | 1.8 months vs 3 months | 5.1 months vs 13.3 months | 9 |
| Jwa Hoon Kim (33) | Esophageal squamous cell carcinoma | 1.9 months vs NK | 6.4 months vs NK | 8 |
| Ka Shing Cheung (34) | hepatocellular carcinoma | NK | NK | 7 |
| Katharina Pomej (35) | HCC | 3.5 months vs 4.8 months | 4.7 months 11.4 months | 8 |
| Kazuyuki Hamada (36) | NSCLC | NK | 8.12 months vs 28.7 months | 8 |
| Kosuke Ueda (37) | RCC | 2.8 months vs 18.4 months | NK | 8 |
| L. Derosa (38) | NSCLC,RCC | 1.9 months vs 7.4 months | 17.3 months vs 30.6 months | 9 |
| Laura M. Chambers (39) | Endometrial carcinoma Cervical carcinoma; Cvarian carcinoma |
7.3 months vs NK | 11.6 months vs NK | 7 |
| Louis Gaucher (40) | Lung, Melanoma, Renal and urothelial, Head and neck, Hodgkin’s lymphoma, Digestive, Cutaneous squamous cell carcinoma, Adenocarcinoma of unknown primary, Squamous cell carcinoma of unknown, Porocarcinoma |
43.0 months vs 96.9 months | 36.1 months vs 86.3 months | 9 |
| M. Chalabi (41) | NSCLC | NK | 8.5 months vs 11.0 months | 7 |
| Megan Greally (42) | Advanced Esophagogastric Cancer | 1.2 months vs 1.8 months | 2.0 months vs 6.4 months | 8 |
| Metges J (43) | malignant melanoma and lung cancer | NK | NK | 6 |
| Min Jung Geum (44) | NSCLC | NK | NK | 7 |
| Nadina Tinsley (45) | melanoma, non-small cell lung cancer, renal cell carcinoma | 3.1 months vs 6.3 months | 10.4 months vs 21.7 months | 8 |
| Nobuaki Ochi (46) | nonesmall-cell lung cancer | 3.5 months vs 3.5 months | 11.7 months vs 16.1 months | 8 |
| Petros Fessas (47) | HCC | 4.4 months vs 7.2 months | 15.4 months vs 16.4 months | 7 |
| Pierre-Yves Cren (48) | advanced melanoma | 7.3 months vs 2.4 months | 15.4 months vs 14.5 months | 8 |
| Po-Hsien Lu MS (49) | NSCLC | 8.87 months vs 15.17 months | 4.03 days vs 12.3 months | 7 |
| Quentin (50) | non-small cell lung carcinoma, melanoma, upper airway carcinoma, digestive tract carcinoma renal cell carcinoma |
NK | NK | 6 |
| Sha Zhao (51) | NSCLC | 3.7 months vs 9.6 months | 6 months vs 21.9 months | 8 |
| Steven R. Hwang (52) | Hodgkin lymphoma | NK | NK | 6 |
| Taiki Hakozaki (53) | NSCLC | 5.2 months vs NK | 16.2 months vs NK | 7 |
| Uqba Khan (9) | NK | NK | NK | 6 |
| X. Mielgo Rubio (54) | NSCLC | NK | NK | 6 |
| Ying Jing (55) | Lung cancer, Liver cancer, Esophageal cancer, Head and neck cancer, Cholangiocarcinoma, Cervical cancer, Lymphoma, Sarcoma, Other |
NK | NK | 6 |
NK, not known.